Tirdzniecība ANI Pharma - ANIP CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.59 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.030779% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | -0.013666% | ||||||||
| Nakts laika nodeva | 22:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 44.95 |
| Atvērt* | 44.62 |
| Izmaiņas par 1 gadu* | 15.24% |
| Dienas Diapazons* | 43.89 - 44.99 |
| 52 ned Diapazons | 22.31-45.50 |
| Vidējais apjoms (10 dienas) | 50.25K |
| Vidējais apjoms (3 mēneši) | 1.50M |
| Tirgus Kapitalizācija | 789.58M |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 17.48M |
| Ieņēmumi | 283.08M |
| EPS | -4.48 |
| Dividende (Ienesīgums %) | N/A |
| Beta | 1.06 |
| Nākamās Peļņas Datums | Mar 13, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Feb 3, 2023 | 44.62 | 0.99 | 2.27% | 43.63 | 45.36 | 43.63 |
| Feb 2, 2023 | 44.95 | 2.66 | 6.29% | 42.29 | 45.17 | 42.29 |
| Feb 1, 2023 | 44.26 | 1.04 | 2.41% | 43.22 | 45.42 | 43.22 |
| Jan 31, 2023 | 44.55 | 1.71 | 3.99% | 42.84 | 44.66 | 42.51 |
| Jan 30, 2023 | 42.94 | 0.97 | 2.31% | 41.97 | 43.13 | 41.96 |
| Jan 27, 2023 | 43.56 | 1.59 | 3.79% | 41.97 | 43.68 | 41.97 |
| Jan 26, 2023 | 43.49 | 0.69 | 1.61% | 42.80 | 43.98 | 42.30 |
| Jan 25, 2023 | 43.35 | 0.38 | 0.88% | 42.97 | 43.56 | 41.96 |
| Jan 24, 2023 | 43.47 | 0.71 | 1.66% | 42.76 | 43.78 | 42.15 |
| Jan 23, 2023 | 42.93 | 2.97 | 7.43% | 39.96 | 43.14 | 39.96 |
| Jan 20, 2023 | 41.96 | 1.98 | 4.95% | 39.98 | 42.01 | 39.98 |
| Jan 19, 2023 | 41.59 | 1.01 | 2.49% | 40.58 | 41.68 | 40.56 |
| Jan 18, 2023 | 41.55 | 0.57 | 1.39% | 40.98 | 42.26 | 40.79 |
| Jan 17, 2023 | 41.79 | -1.57 | -3.62% | 43.36 | 43.61 | 41.79 |
| Jan 13, 2023 | 43.90 | 1.58 | 3.73% | 42.32 | 44.11 | 41.45 |
| Jan 12, 2023 | 42.89 | 2.08 | 5.10% | 40.81 | 42.99 | 40.81 |
| Jan 11, 2023 | 41.18 | -0.35 | -0.84% | 41.53 | 42.49 | 40.63 |
| Jan 10, 2023 | 42.21 | 0.80 | 1.93% | 41.41 | 42.38 | 40.59 |
| Jan 9, 2023 | 42.22 | -1.25 | -2.88% | 43.47 | 43.77 | 40.96 |
| Jan 6, 2023 | 43.71 | 4.09 | 10.32% | 39.62 | 44.55 | 39.41 |
ANI Pharma Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Kopējie ienākumi | 128.622 | 176.842 | 201.576 | 206.547 | 208.475 | 216.136 |
| Ienākumi | 128.622 | 176.842 | 201.576 | 206.547 | 208.475 | 216.136 |
| Cost of Revenue, Total | 48.78 | 79.032 | 73.024 | 63.154 | 87.157 | 100.61 |
| Bruto Peļņa | 79.842 | 97.81 | 128.552 | 143.393 | 121.318 | 115.526 |
| Kopējie Darbības Izdevumi | 108.543 | 148.513 | 166.217 | 190.196 | 224.491 | 255.929 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 27.829 | 31.58 | 44.063 | 55.843 | 64.986 | 84.294 |
| Pētniecība un Attīstība | 2.906 | 9.07 | 15.388 | 19.806 | 16.001 | 11.369 |
| Depreciation / Amortization | 22.343 | 27.928 | 33.742 | 44.612 | 44.638 | 47.252 |
| Neparedzēti Izdevumi (Ienākumi) | 6.685 | 0.903 | 0 | 6.781 | 11.709 | 11.904 |
| Darbības Izdevumi | 20.079 | 28.329 | 35.359 | 16.351 | -16.016 | -39.793 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -11.327 | -12.035 | -14.758 | -12.966 | -9.452 | -11.922 |
| Citi, Neto | -0.074 | 0.055 | -0.55 | -0.228 | -0.494 | -4.343 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 8.678 | 16.349 | 20.051 | 3.157 | -25.962 | -56.058 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 3.934 | 12.324 | 15.494 | 6.094 | -22.548 | -42.603 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 3.934 | 12.324 | 15.494 | 6.094 | -22.548 | -42.603 |
| Neto Ienākumi | 3.934 | -1.076 | 15.494 | 6.094 | -22.548 | -42.603 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 3.934 | 12.324 | 15.34 | 5.997 | -22.548 | -42.793 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 3.934 | -1.076 | 15.34 | 5.997 | -22.548 | -42.793 |
| Atšķaidītie Neto Ienākumi | 3.934 | -1.076 | 15.34 | 5.997 | -22.548 | -42.793 |
| Atšķaidītie Ienākumi par Akcijām | 11.573 | 11.547 | 11.772 | 12.04 | 11.964 | 12.596 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 0.33993 | 1.06729 | 1.30309 | 0.49809 | -1.88465 | -3.39735 |
| Atšķaidītā Normalizētā Peļņa par Akciju | 0.60179 | 1.12624 | 1.30309 | 0.86417 | -1.24851 | -2.78306 |
| Ārkārtas Posteņi Kopā | -13.4 | |||||
| Total Adjustments to Net Income | 0 | -0.154 | -0.097 | -0.19 | ||
| Other Operating Expenses, Total | 0.5 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 54.521 | 48.625 | 52.061 | 60.929 | 64.477 |
| Ienākumi | 54.521 | 48.625 | 52.061 | 60.929 | 64.477 |
| Cost of Revenue, Total | 19.985 | 22.314 | 24.413 | 33.898 | 34.271 |
| Bruto Peļņa | 34.536 | 26.311 | 27.648 | 27.031 | 30.206 |
| Kopējie Darbības Izdevumi | 51.476 | 64.178 | 55.623 | 84.652 | 83.672 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 17.587 | 18.82 | 17.181 | 30.706 | 28.817 |
| Pētniecība un Attīstība | 2.968 | 2.805 | 2.456 | 3.14 | 5.274 |
| Depreciation / Amortization | 10.898 | 11.324 | 11.346 | 13.684 | 14.557 |
| Neparedzēti Izdevumi (Ienākumi) | 0.038 | 8.915 | 0.227 | 2.724 | 0 |
| Darbības Izdevumi | 3.045 | -15.553 | -3.562 | -23.723 | -19.195 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -2.454 | -2.531 | -2.497 | -4.44 | -6.613 |
| Citi, Neto | -0.515 | -0.067 | -1.071 | -2.69 | -0.089 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 0.076 | -18.151 | -7.13 | -30.853 | -25.897 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 0.086 | -14.106 | -4.447 | -24.136 | -20.13 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 0.086 | -14.106 | -4.447 | -24.136 | -20.13 |
| Neto Ienākumi | 0.086 | -14.106 | -4.447 | -24.136 | -20.13 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 0.086 | -14.106 | -4.447 | -24.326 | -20.535 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 0.086 | -14.106 | -4.447 | -24.326 | -20.535 |
| Atšķaidītie Neto Ienākumi | 0.086 | -14.106 | -4.447 | -24.326 | -20.535 |
| Atšķaidītie Ienākumi par Akcijām | 12.017 | 12.085 | 12.107 | 14.186 | 16.137 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 0.00716 | -1.16723 | -0.36731 | -1.71479 | -1.27254 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | 0.00921 | -0.68773 | -0.35512 | -1.58998 | -1.27254 |
| Other Operating Expenses, Total | 0.5 | 0.753 | |||
| Total Adjustments to Net Income | -0.19 | -0.405 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 103.007 | 131.605 | 152.877 | 187.695 | 170.321 | 321.775 |
| Nauda un Īstermiņa Ieguldījumi | 27.365 | 31.144 | 43.008 | 62.332 | 7.864 | 100.3 |
| Nauda un Ekvivalenti | 27.365 | 31.144 | 43.008 | 62.332 | 7.864 | 100.3 |
| Debitoru Parādu Kopsumma, Neto | 45.895 | 59.95 | 64.842 | 73.205 | 95.793 | 132.193 |
| Accounts Receivable - Trade, Net | 45.895 | 58.788 | 64.842 | 72.129 | 95.793 | 128.526 |
| Total Inventory | 26.183 | 37.727 | 40.503 | 48.163 | 60.803 | 81.693 |
| Prepaid Expenses | 3.564 | 2.784 | 4.524 | 3.995 | 5.861 | 7.589 |
| Total Assets | 322.864 | 412.138 | 430.604 | 456.789 | 461.19 | 771.598 |
| Property/Plant/Equipment, Total - Net | 10.998 | 20.403 | 38.09 | 40.551 | 41.269 | 52.671 |
| Property/Plant/Equipment, Total - Gross | 16.385 | 26.992 | 46.491 | 53.321 | 58.796 | 75.627 |
| Accumulated Depreciation, Total | -5.387 | -6.589 | -8.401 | -12.77 | -17.527 | -22.956 |
| Goodwill, Net | 1.838 | 1.838 | 3.58 | 3.58 | 3.58 | 27.888 |
| Intangibles, Net | 175.792 | 229.79 | 201.604 | 180.388 | 188.511 | 294.122 |
| Other Long Term Assets, Total | 31.229 | 28.502 | 34.453 | 44.575 | 57.509 | 75.142 |
| Total Current Liabilities | 31.948 | 39.228 | 165.549 | 61.676 | 78.565 | 87.537 |
| Accounts Payable | 3.389 | 3.63 | 8.884 | 14.606 | 11.261 | 22.967 |
| Accrued Expenses | 20.405 | 23.971 | 22.661 | 20.083 | 22.92 | 27.802 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 8.154 | 8.274 | 18.285 | 17.046 | 31.141 | 35.918 |
| Total Liabilities | 153.216 | 237.382 | 233.341 | 243.998 | 265.49 | 412.858 |
| Total Long Term Debt | 120.643 | 198.154 | 67.296 | 175.808 | 172.443 | 286.52 |
| Long Term Debt | 120.643 | 198.154 | 67.296 | 175.808 | 172.443 | 286.52 |
| Other Liabilities, Total | 0.625 | 0 | 0.496 | 6.514 | 14.482 | 38.801 |
| Total Equity | 169.648 | 174.756 | 197.263 | 212.791 | 195.7 | 358.74 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 24.85 | |
| Common Stock | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
| Additional Paid-In Capital | 172.563 | 179.02 | 186.812 | 200.8 | 214.354 | 387.844 |
| Retained Earnings (Accumulated Deficit) | -2.916 | -4.006 | 11.488 | 17.584 | -4.972 | -47.765 |
| Total Liabilities & Shareholders’ Equity | 322.864 | 412.138 | 430.604 | 456.789 | 461.19 | 771.598 |
| Total Common Shares Outstanding | 11.5996 | 11.6614 | 11.8622 | 12.1004 | 12.3653 | 16.8406 |
| Current Port. of LT Debt/Capital Leases | 3.353 | 115.719 | 9.941 | 13.243 | 0.85 | |
| Treasury Stock - Common | -0.259 | -0.659 | -0.723 | -2.246 | -3.135 | |
| Other Equity, Total | -0.379 | -4.871 | -11.437 | -3.055 | ||
| Total Preferred Shares Outstanding | 0.025 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 182.798 | 191.799 | 191.384 | 321.775 | 301.399 |
| Nauda un Īstermiņa Ieguldījumi | 25.073 | 24.261 | 15.254 | 100.3 | 76.911 |
| Nauda un Ekvivalenti | 25.073 | 24.261 | 15.254 | 100.3 | 76.911 |
| Debitoru Parādu Kopsumma, Neto | 91.876 | 95.023 | 109.744 | 132.193 | 133.607 |
| Accounts Receivable - Trade, Net | 91.876 | 92.648 | 106.714 | 128.526 | 131.625 |
| Total Inventory | 59.927 | 67.634 | 61.684 | 81.693 | 83.155 |
| Prepaid Expenses | 5.922 | 4.881 | 4.702 | 7.589 | 7.726 |
| Total Assets | 463.843 | 480.159 | 470.454 | 771.598 | 744.846 |
| Property/Plant/Equipment, Total - Net | 40.767 | 40.334 | 39.526 | 52.671 | 52.713 |
| Property/Plant/Equipment, Total - Gross | 59.541 | 60.336 | 60.816 | 75.627 | 77.677 |
| Accumulated Depreciation, Total | -18.774 | -20.002 | -21.29 | -22.956 | -24.964 |
| Goodwill, Net | 3.58 | 3.58 | 3.58 | 27.888 | 28.188 |
| Intangibles, Net | 178.859 | 180.199 | 170.141 | 294.122 | 281.573 |
| Other Long Term Assets, Total | 57.839 | 64.247 | 65.823 | 75.142 | 80.973 |
| Total Current Liabilities | 82.768 | 89.454 | 84.872 | 87.537 | 79.532 |
| Accounts Payable | 13.769 | 12.977 | 11.513 | 22.967 | 22.059 |
| Accrued Expenses | 21.896 | 29.329 | 25.141 | 27.802 | 20.953 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 14.438 | 15.182 | 15.927 | 0.85 | 0.85 |
| Other Current Liabilities, Total | 32.665 | 31.966 | 32.291 | 35.918 | 35.67 |
| Total Liabilities | 260.131 | 288.242 | 279.051 | 412.858 | 398.752 |
| Total Long Term Debt | 168.985 | 189.525 | 186.063 | 286.52 | 286.307 |
| Long Term Debt | 168.985 | 189.525 | 186.063 | 286.52 | 286.307 |
| Other Liabilities, Total | 8.378 | 9.263 | 8.116 | 38.801 | 32.913 |
| Total Equity | 203.712 | 191.917 | 191.403 | 358.74 | 346.094 |
| Common Stock | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
| Additional Paid-In Capital | 216.223 | 219.403 | 222.211 | 387.844 | 391.084 |
| Retained Earnings (Accumulated Deficit) | -4.886 | -18.992 | -23.439 | -47.765 | -68.3 |
| Treasury Stock - Common | -2.594 | -3.062 | -3.135 | -3.135 | -4.253 |
| Other Equity, Total | -5.032 | -5.433 | -4.235 | -3.055 | 2.712 |
| Total Liabilities & Shareholders’ Equity | 463.843 | 480.159 | 470.454 | 771.598 | 744.846 |
| Total Common Shares Outstanding | 12.7546 | 12.7564 | 12.7517 | 16.8406 | 17.2619 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 24.85 | 24.85 | |
| Total Preferred Shares Outstanding | 0.025 | 0.025 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | 3.934 | -1.076 | 15.494 | 6.094 | -22.548 | -42.603 |
| Nauda no Darbības | 27.472 | 39.419 | 67.074 | 45.631 | 15.267 | 3.322 |
| Nauda no Darbības | 22.343 | 27.928 | 33.742 | 44.612 | 44.638 | 47.252 |
| Deferred Taxes | -8.911 | 3.56 | -5.18 | -9.134 | -13.205 | -16.754 |
| Bezskaidras Naudas Preces | 20.033 | 14.659 | 17.05 | 18.64 | 19.01 | 15.511 |
| Cash Taxes Paid | 9.537 | 17.786 | 6.397 | 10.033 | 4.984 | 10.371 |
| Samaksātie Procenti Naudā | 4.078 | 3.759 | 6.285 | 6.092 | 6.931 | 9.705 |
| Izmaiņas Apgrozāmajā Kapitālā | -9.927 | -5.652 | 5.968 | -14.581 | -12.628 | -0.084 |
| Nauda no Ieguldījumu Darbībām | -149.06 | -107.993 | -27.379 | -27.549 | -68.322 | -105.483 |
| Kapitālie Izdevumi | -4.566 | -10.369 | -5.743 | -6.635 | -6.135 | -2.557 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | -144.494 | -97.624 | -21.636 | -20.914 | -62.187 | -102.926 |
| Nauda no Darbībām ar Finansēšanu | -0.729 | 72.357 | -27.816 | 1.25 | -1.439 | 194.595 |
| Naudas Plūsma Finansēšanas Posteņos | 0.323 | -2.737 | -1.197 | 0 | -19.384 | |
| Akciju Izsniegšana (Atkāpšanās), Neto | -1.052 | 0.094 | 2.319 | 4.707 | -0.905 | 101.179 |
| Parādu Izsniegšana (Atkāpšanās), Neto | 0 | 75 | -28.938 | -3.457 | -0.534 | 112.99 |
| Neto Izmaiņas Naudā | -122.317 | 3.783 | 11.879 | 19.332 | -54.494 | 92.434 |
| Total Cash Dividends Paid | -0.19 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 0.086 | -14.02 | -18.467 | -42.603 | -20.13 |
| Cash From Operating Activities | 20.668 | 20.909 | 15.507 | 3.322 | -18.942 |
| Cash From Operating Activities | 10.898 | 22.222 | 33.568 | 47.252 | 14.557 |
| Deferred Taxes | -0.279 | -6.676 | -8.665 | -16.754 | -7.464 |
| Non-Cash Items | 2.441 | 5.854 | 9.239 | 15.511 | 4.972 |
| Cash Taxes Paid | 0.112 | 8.36 | 8.36 | 10.371 | 0 |
| Cash Interest Paid | 1.983 | 3.953 | 5.922 | 9.705 | 5.637 |
| Changes in Working Capital | 7.522 | 13.529 | -0.168 | -0.084 | -10.877 |
| Cash From Investing Activities | -0.737 | -22.687 | -23.27 | -105.483 | -2.178 |
| Capital Expenditures | -0.698 | -1.63 | -2.201 | -2.557 | -1.949 |
| Other Investing Cash Flow Items, Total | -0.039 | -21.057 | -21.069 | -102.926 | -0.229 |
| Cash From Financing Activities | -2.725 | 18.173 | 15.151 | 194.595 | -2.27 |
| Issuance (Retirement) of Stock, Net | -0.348 | -0.48 | -0.553 | 101.179 | -1.115 |
| Issuance (Retirement) of Debt, Net | -2.377 | 18.794 | 15.966 | 112.99 | -0.75 |
| Net Change in Cash | 17.206 | 16.395 | 7.388 | 92.434 | -23.39 |
| Financing Cash Flow Items | -0.141 | -0.262 | -19.384 | ||
| Total Cash Dividends Paid | -0.19 | -0.405 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| Meridian Venture Partners | Private Equity | 11.5692 | 2019259 | -200000 | 2022-12-01 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 10.3137 | 1800130 | -59445 | 2022-09-30 | LOW |
| Esjay L.L.C, | Corporation | 7.6351 | 1332620 | 0 | 2022-03-10 | LOW |
| Emerald Advisers LLC | Investment Advisor | 4.5557 | 795146 | -17599 | 2022-09-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.5039 | 786099 | -26251 | 2022-09-30 | LOW |
| William Blair Investment Management, LLC | Investment Advisor/Hedge Fund | 3.1362 | 547389 | -9665 | 2022-09-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 3.0105 | 525449 | -13294 | 2022-09-30 | LOW |
| Medical Strategy GmbH | Investment Advisor | 2.7459 | 479272 | 0 | 2022-09-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.5982 | 453480 | -12244 | 2022-09-30 | LOW |
| Global Alpha Capital Management Ltd. | Investment Advisor | 2.4025 | 419331 | 95600 | 2022-09-30 | LOW |
| Thompson, Siegel & Walmsley LLC | Investment Advisor | 2.3832 | 415962 | -19911 | 2022-09-30 | LOW |
| First Wilshire Securities Management, Inc. | Investment Advisor/Hedge Fund | 2.1046 | 367326 | -428 | 2022-09-30 | LOW |
| Kennedy Capital Management, Inc. | Investment Advisor | 1.962 | 342450 | 180376 | 2022-09-30 | LOW |
| AIGH Capital Management, LLC. | Private Equity | 1.8014 | 314406 | 69906 | 2022-09-30 | MED |
| Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 1.7544 | 306210 | 2702 | 2022-09-30 | LOW |
| Rubric Capital Management LP | Hedge Fund | 1.6446 | 287046 | 204602 | 2022-09-30 | MED |
| Lalwani (Nikhil Suresh) | Individual Investor | 1.6154 | 281957 | -3646 | 2022-09-08 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3108 | 228792 | -3053 | 2022-09-30 | LOW |
| Carey (Stephen P.) | Individual Investor | 0.8401 | 146633 | 5845 | 2022-04-27 | LOW |
| Balyasny Asset Management LP | Hedge Fund | 0.7961 | 138949 | 138949 | 2022-09-30 | HIGH |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group +485000+
Tirgotāji
65000+
Ikmēneša aktīvie klienti
$48000000+
Ikmēneša ieguldījumu apjoms
$28000000+
Izmēģināt tagad Izņemts katru mēnesi
Treidinga kalkulators
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Tirdzniecības komisija
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Finanšu svira
20:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
ANI Pharma Company profile
Par ANI Pharma
ANI Pharmaceuticals, Inc. ir integrēts specializēts farmācijas uzņēmums. Uzņēmums koncentrējas uz zīmolu un ģenērisko recepšu zāļu izstrādi, ražošanu un tirdzniecību. Uzņēmums koncentrējas uz tādām jomām kā kontrolējamās vielas, onkoloģiskie produkti (pretvēža līdzekļi), hormoni un steroīdi, kā arī sarežģīti preparāti. Sabiedrības produkti ietver gan zīmolu, gan ģenēriskos farmaceitiskos līdzekļus. Tās ģenērisko zāļu klāstā ir šādi produkti: Aspirīns un dipiridamols ar pagarinātu atbrīvošanu, Bretylium Tosylate Injection USP, holestiramīns, Etodolac, Fluvoksamīns, Indapamīds, Nilutamīds, Vankomicīns un citi. Tās zīmolu produkti ir Arimidex (anastrozols) tabletes, Atacand HCT tabletes, Atacand (kandesartāna cileksetila) tabletes, Casodex, Cortenema, Cortrophin gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan un Vancocin. Uzņēmums darbojas trijās farmācijas ražotnēs, no kurām divas atrodas Baudette, Minesotas štatā, un viena - Oakville, Ontario štatā.
| Industry: | Pharmaceuticals (NEC) |
210 Main Street West
BAUDETTE
MINNESOTA 56623
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 485 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com